Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an antibody or an antigen-binding fragment thereof covalently linked to at least one BH3 mimetic through a dual linker. The disclosure further relates to methods and compositions for use...

Full description

Saved in:
Bibliographic Details
Main Authors D'ALESSIO, JOSEPH ANTHONY, HOLLINGWORTH, GREGORY JOHN, ROCCHETTI, FRANCESCA, MUNDT, CORNELIA ANNE, MARAGNO, ANA LETICIA, LANGLOIS, JEAN-BAPTISTE, MADORIN, KATHARINA, FEJES, IMRE, KLINTER, CLAUDIA JUDITH, MCNEILL, ERIC ANDREW, STARCK, JEROME BENOIT, GENESTE, OLIVIER, YU, BING, ZHANG, QIANG, CHEN, ZHUO-LIANG, NAKAJIMA, KATSUMASA, BURGER, MATTHEW T, RAY, STUART, NEWCOMBE, RICHARD VAUGHAN, SZLAVIK, ZOLTAN
Format Patent
LanguageChinese
English
Published 01.03.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an antibody or an antigen-binding fragment thereof covalently linked to at least one BH3 mimetic through a dual linker. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising at least one BH3 mimetic and methods of making the same are also disclosed.
Bibliography:Application Number: TW202312118818